@Hunterr Look at it this way..... (This is all just IMO - DYOR etc)
16th June 2020 - (SP approximately 40c)
ASX announcement, "Impressive 40% clinical response rate in Phase II Bisantrene AML Trial"
The results of this phase II trial were reported to the market straight away. And these were "Impressive" results.
5th November 2020 - (SP approximately $1.00)
ASX announcement, "Phase II Bisantrene trial data to be presented at ASH 2020"
They waited until November to inform us of the ASH presentation.
11th November 2020 - (SP approximately $1.40)
ASX announcement, "Phase II Bisantrene trial data published in European Journal of Haematology"
This announcement had a link to the doi - doi.org/10.1111/ejh.13544 - where we were able to see the intricate details of the trial results (they were GOOD!)
27th November 2020 - (SP approximately $2.15)
...... So let us keep the above in mind when we think of what we've been told about Sheba 2.0....
27th May 2022 -
ASX announcement, "Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2"
Within the announcement, "Encouraging clinical responses were observed in this very heavily pre-treated AML patient population with 3 of the 6 patients bridged to a stem cell transplant"
"The six patients were heavily pre-treated and had received a median of four prior lines of AML treatment (range 2-8)"
"If three or more of the patients treated in Stage 2 respond, the null hypothesis of treatment futility can be rejected.".... In simple terms, the statement is saying that if three or more patients in Stage 2 respond positively to the treatment, there is evidence to conclude that the treatment is not futile, and it may be effective.
7th July 2023 -
ASX announcement, "H1 2023 Preclincal and Clinical Programs Update" - clinical programs
Within the announcement, "To date, 20 heavily pre-treated patients with relapsed and refractory AML have been enrolled, with only two further patients required to meet the first stage of the Simon two-stage decision point. Observations in this open-label protocol have been compelling, with several patients
being effectively bridged to allogeneic stem cell transplant with curative intent."
** "compelling", "several", "curative intent" ****
"Sheba investigational team is now working towards assembling the data for publication in a peer-reviewed journal followed by a report to the market on the study outcomes."
..... This time around they have decided to hold back the results until ASH and the publication in a journal.
My educated guess is that the "compelling" observations in this trial show a response rate of over 50%. When considering these are heavily pre-treated patients, over 50% would be good to see.
With any luck, after the 2nd of November, the market will wake up, and $2 will be in the review mirror for good!
9th October 2023 - (SP approximately 80c)
30th November 2023 - (SP approximately..........????)
IMO, DYOR, GLTAH, IYASYGS, etc
(20min delay)